L
L. Kim
Researcher at Janssen Pharmaceutica
Publications - 26
Citations - 567
L. Kim is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Golimumab & Placebo. The author has an hindex of 9, co-authored 24 publications receiving 458 citations. Previous affiliations of L. Kim include Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Joel M. Kremer,Christopher T. Ritchlin,Alan M. Mendelsohn,Daniel Baker,L. Kim,Zhenhua Xu,J. Han,Peter C. Taylor +7 more
TL;DR: Inter intravenously administered golimumab plus MTX appears to have benefit in the longer-term reduction of RA signs/symptoms in MTX-resistant patients, with no unexpected safety concerns.
Journal ArticleDOI
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
Michael E. Weinblatt,Clifton O. Bingham,Alan M. Mendelsohn,L. Kim,Michael Mack,J. Lu,Daniel Baker,Rene Westhovens +7 more
TL;DR: The addition of intravenous golimumab rapidly and significantly improved signs and symptoms in patients with active RA despite ongoing MTX, in some patients by week 2.
Journal ArticleDOI
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
Hermine I. Brunner,Nicolino Ruperto,Nikolay Tzaribachev,Gerd Horneff,Vyacheslav Chasnyk,Violeta Panaviene,Carlos Abud-Mendoza,Andreas Reiff,Ekaterina Alexeeva,Nadina Rubio-Pérez,Vladimir Keltsev,Daniel J. Kingsbury,Maria Del Rocio Maldonado Velázquez,Irina Nikishina,Earl D. Silverman,Rik Joos,Elżbieta Smolewska,Marcia Bandeira,Kirsten Minden,Annet van Royen-Kerkhof,W. Emminger,Ivan Foeldvari,Bernard Lauwerys,Flavio Sztajnbok,Keith Gilmer,Zhenhua Xu,Jocelyn H. Leu,L. Kim,S. Lamberth,Matthew J. Loza,Daniel J. Lovell,Alberto Martini +31 more
TL;DR: Although the primary endpoint was not met, golimumab resulted in rapid, clinically meaningful, improvement in children with active polyJIA, and Golimumab was well tolerated, and no unexpected safety events occurred.
Journal ArticleDOI
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Arthur Kavanaugh,M. Elaine Husni,Diane D. Harrison,L. Kim,Kim Hung Lo,Jocelyn H. Leu,Elizabeth C. Hsia +6 more
TL;DR: The objective was to evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA) and to establish a protocol for future studies.
Journal ArticleDOI
Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial
Michael E. Weinblatt,Rene Westhovens,Alan M. Mendelsohn,L. Kim,Kim Hung Lo,Shihong Sheng,L. Noonan,J. Lu,Zhenhua Xu,Jocelyn H. Leu,Daniel Baker,Clifton O. Bingham +11 more
TL;DR: In patients with active RA despite MTX, intravenous golimumab+MTX yielded significant inhibition of structural damage at wk24 and wk52, and sustained clinical improvement in signs and symptoms with no new safety signals up to 1 year.